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Abstract 
 
Umbilical cord blood (UCB) is an alternative hematopoietic stem cell (HSC) source that can 
ameliorate several diseases through transplantation. The purpose of this project is to analyze 
clinical studies comparing HSCs from a single cord blood unit (CBU) to HSCs from bone 
marrow, and to explore methods of increasing limited amounts of HSCs. It was found that UCB 
transplantation in adults is a viable method when a matched bone marrow transplant cannot be 
identified. Further clinical studies using two CBUs suggest better engraftment and lower risk of 
relapse. However, double cord blood transplantation has been faced with the challenge of single 
unit dominance in most studies. Ex vivo expansion of UCB HSCs is another promising method to 
overcome limited HSC counts.  
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The findings of this IQP have been complied as a 
journal article. The article has been submitted to the Global 
Journal of Health Science for publication. 
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I. Introduction 
Every year, thousands of patients are diagnosed with blood disorders and diseases such as 
leukemia, lymphoma and sickle cell anemia. Such disorders and diseases are usually cured by 
bone marrow transplants. The stem cells within the bone marrow are typically obtained from the 
family members of the patient or bone marrow registries. However, finding bone marrow stem 
cells that will be compatible, or genetically similar, to that of the patient is a difficult task.  Such 
sources are also very limited.  Often times, bone marrow donations from family members have a 
25% chance of being compatible with the cells of the patient.  A new method for curing such 
blood disorders and diseases has emerged as a potential alternative through the use of stem cells 
obtained from the umbilical cord blood. 
 In the 1970s, researchers considered umbilical cord blood, originally thrown away after 
delivery of the baby, as a potential source of stem cells. In the 1980s, researchers and doctors 
successfully transplanted stem cells extracted from the umbilical cord blood to cure a boy who 
had a genetic disease known as Fanconi Anemia, which causes bone marrow defects that result 
in the inability to produce blood cells. From then on, scientists have performed extensive 
research to explore the potential therapeutic uses of umbilical cord blood, or simply known as 
cord blood. To date, there are more than 70 diseases that can be potentially treated by the use of 
stem cells from cord blood. 
Scientists have provided evidence that the umbilical cord contains blood that is enriched 
with stem cells, known as hematopoietic (blood-forming) stem cells. According to Melinda Beck 
from the Wall Street Journal, ―two tablespoons of umbilical cord blood contains about one 
billion stem cells‖, compared to 140 billion red blood cells in two tablespoons. Although small in 
number compared to red blood cells, these stem cells may be used to cure genetic diseases, blood 
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disorders, and certain cancers.  Currently, about 600,000 cord blood units are stored in cord 
blood banks and there have been about 20,000 (3.3%) transplants, more than any human organ 
transplant excluding the kidney. 
 Transplants performed with cord blood have various advantages over other types of 
transplants.  Stem cells from the cord blood are more likely to be a match with a wider variety of 
patients as opposed to the more specific match when considering bone marrow transplants.  
Moreover, research has shown that the median time to find a compatible match with a cord blood 
is much shorter than with a bone marrow transplant. Another advantage is the noninvasive nature 
of the procedure.  While bone marrow transplants may inflict some pain to the donor, cord blood 
permits easy access to stem cells with no pain to the mother or the newborn.  
A disadvantage of cord blood transplants, compared to bone marrow transplants, is that 
the patient takes longer to recover.  However, cord blood stem cells have the same healing 
effects as bone marrow stem cells.  Another disadvantage of cord blood transplants is the 
reduced concentration of stem cells.  Most adults will require at least 2 units of cord blood in 
order to experience the full healing effect. 
 Despite certain disadvantages, cord blood has enormous potential in medical treatment. 
Consequently cord blood has been collected and stored worldwide. In the United States, there are 
many hospitals that collect cord blood, using simple collection kits.  The kits, mostly used by 
nurses in the facility, contain simple instructions on the collection process.  Once collected, the 
cord blood unit is shipped to a cord blood bank. 
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  I         II            III 
Figure 1. (I) Cord blood collection kit, (II and III) Contents of the collection kit 
There are two types of cord blood banks, public and private.  A public bank, the more 
popular of the two, is the donation of stem cells of the baby to a public registry. Anyone can 
have access to the stem cells on a first-come first-serve basis. The donation is done with the 
consent of the mother and at no cost to the family. However, not all mothers meet the donation 
criteria.  Some exclusions include mothers who have inadequate amounts of cord blood, have 
been through multiple gestations, have had a history of cancer, blood disease, and so on.  When a 
patient needs a cord blood transplant, he/she will have up to a 90% chance of finding a match, a 
unit compatible with the cells of the patient, in a public bank.  The costs of the transplant, which 
are generally covered by insurance, usually range from $15,000-$25,000.  There are 38 public 
bank donation programs in the U.S.  In Massachusetts, Brigham and Women‘s hospital1 collects 
cord blood and is in partnership with Carolinas Cord Blood Bank, a public bank. 
 Private banking stores cord blood exclusively for the family of the newborn.  This type of 
banking is typically chosen by mothers who have had a history of a particular disease in their 
family that may require a stem cell transplant in the future.  The cord blood transplant is 
guaranteed to be 100% compatible with the child of the mother.  However, this percentage 
decreases drastically to 25% compatibility with anyone else in the family.  In order to bank 
privately, it costs about $1500 to begin banking and $150-$200 annually.  When a transplant is 
8 
 
needed, the cord blood unit is released with or without any charge depending on the bank. There 
are 34 private banks in the U.S.  In Massachusetts, UMASS Memorial hospital
2
 collects cord 
blood and is in partnership with Lifeforce Cryobanks, a public and private facility. 
Cord blood banking has been prospering since it was first established in the 1990s. This 
alternative to bone marrow stem cells is much more available and has been effective in saving 
many lives.  Current research is exploring better purification, collection, and storage methods of 
these stem cells.  Financially, excluding insurance, cord blood provides a reasonable value for 
cord blood transplants, $15,000-25,000, compared to $250,000 for a bone marrow transplant 
which is a $235,000 saving.  
This IQP aims to provide researchers in the field of umbilical cord blood transplantation 
with intensive technical information. Essential constituents of the cord blood and their roles in 
clinical uses were first investigated. Hematopoietic stem cell transplantation, different 
conditioning regimens used to treat the patients and clinical results of studies performed on bone 
marrow transplants and umbilical cord blood transplants were further elucidated. Moreover, two 
methods to enhance the treating potentials of umbilical cord blood were examined, namely 
double cord blood transplantation and ex vivo expansion of cord blood. Additionally this study 
explained the processing and handling of umbilical cord blood, including cord blood extraction, 
cryopreservation, banking and retrieval. Lastly public awareness of umbilical cord blood banking 
was tested on faculty and students at Worcester Polytechnic Institute (Appendix 1).   
 
 
 
 
1
http://www.brighamandwomens.org/womenshealth/corddonor/ 
2
http://www.umassmemorial.org/MedicalCenterIP.cfm?id=4323  
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II. Objectives 
The major objectives of this review are: 
1. To understand the basic physiology of umbilical cord and essential constituents of cord 
blood and their roles in umbilical cord blood transplantation 
2. To understand hematopoietic stem cell transplantation and conditioning regimens, 
namely myeloablative, non-myeloablative and reduced intensity conditionings, treated to 
patients undergoing stem cell transplants 
3. To review and analyze results of clinical studies performed on patients with different 
malignancies using umbilical cord blood transplantation and bone marrow transplantation 
4. To elucidate the advantages and disadvantages between umbilical  cord blood 
transplantation and bone marrow transplantation 
5. To investigate methods to further enhance therapeutic potentials of umbilical cord blood 
transplantations 
a. To examine double cord blood transplantation and to review and analyze results 
of clinical studies performed on patients with different malignancies using double 
cord blood transplantation 
b. To investigate different techniques used to expand umbilical cord blood ex vivo 
6. To understand umbilical cord blood processing and handling for therapeutic uses 
a. To examine umbilical cord blood extraction and cryopreservation 
b. To investigate the differences between private and public cord blood banking 
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7. To investigate public awareness of umbilical cord blood banking 
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III. Methodology 
 The purpose of this study is to investigate the therapeutic potentials and effectiveness of 
the umbilical cord blood. In order to accomplish this goal, numerous clinical research articles 
relating to the clinical studies performed using umbilical cord blood were intensively reviewed. 
Moreover, two informal interviews were conducted at UMASS Medical Center and Auxocell 
Laboratories to obtain further information.  
 The history of umbilical cord blood as a therapeutic tool was investigated and important 
achievements resulted from umbilical cord blood transplantations were described. Essential 
constituents of the umbilical cord blood which contribute to medical applications were 
examined. Furthermore, clinical studies that have been performed recently were investigated and 
results were interpreted and compared. Further research was performed to describe the handling 
and processing of the umbilical cord blood to be used in clinical research.  
 Furthermore, two personal interviews with technical experts in the field were conducted. 
One interview was performed at the UMASS Medical Center with Dr. Mary Herlihy who kindly 
explained blood extraction, collection, banking processes and so on (An audio file recorded 
during the interview is attached) (Appendix II). A second interview was conducted at Auxocell 
Laboratories with Dr. Rouzbeh Taghizadeh, who provided important technical information 
concerning umbilical cord blood (Appendix II).   
In order to disseminate the information to the specific audience of clinical researchers, 
the findings were compiled together as a manuscript for publication at the Global Journal of 
Health Science. Dr Guisheng Song, one of the editorial board members, was contacted regarding 
the publication of the manuscripts. Currently, the manuscript is under reviewing process for 
publication. Email correspondence with Dr. Guisheng Song is included in Appendix II.  
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Abstract 
Umbilical cord blood (UCB) is an alternative hematopoietic stem cell (HSC) source. It is widely applicable for 
ameliorating several diseases through HSC transplants. One of the few disadvantages of this source of stem cells is 
the limited amount of HSCs that can be extracted from each cord blood unit (CBU). Single CBU transplantation 
seems to be more ideal in lower weight, younger patients. Adult clinical studies comparing HSCs from a single CBU 
and HSCs from bone marrow indicate that umbilical cord blood transplantation is a viable method when a matched 
bone marrow transplant cannot be identified. Further clinical studies using two CBUs suggest better engraftment and 
lower risk of relapse. However, double cord blood transplantation has been faced with the challenge of single unit 
dominance in most studies. Ex vivo expansion of UCB HSC is another promising method to overcome limited HSC 
counts.  
Keywords: umbilical cord blood, hematopoietic stem cells, umbilical cord blood transplantation, double cord blood 
transplantation, ex vivo expansion  
1. Introduction 
Originally thrown away after the delivery of the baby, umbilical cord blood (UCB) was first considered as 
a source of stem cells in the 1970s (Mayani, Alvarado-Moreno, & Flores-Guzmán, 2003). Recent advances in the 
potential of UCB have revealed therapeutic uses of HSCs (Eapen et al., 2007; Gluckman et al., 1989; Rocha et al., 
2001). The presence of hematopoietic progenitor cells in human UCB was first evidenced by Knudtzon in 1974 
(Knudtzon, 1974). Approximately 10 years later, the presence of more primitive hematopoietic progenitor cells was 
observed by Leary and Ogawa (Leary & Ogawa, 1987). UCB has the potential to be used as a therapeutic tool due to 
its abilities to engraft (Broxmeyer et al., 1989). In comparison to bone marrow (BM) hematopoietic stem cells 
(HSCs), UCB is easier to attain, more available, and requires less compatibility with the patient.   
UCB has been a successful alternative to BM as a source of HSCs for treating a variety of hematologic 
disorders and malignant/non-malignant diseases such as leukemia, lymphoma, and sickle cell anemia (Broxmeyer, 
2010; Higuchi et al., 2010). UCB was first tested on a young boy who had Fanconi Anemia, an autosomal recessive 
disorder. Fanconi Anemia is characterized by hematological abnormalities and BM failure. The transplant of UCB 
from a female HLA-identical sibling allowed the boy to regenerate all hematopoietic efficacies that were limited by 
the disease (Gluckman et al., 1989). This success has been a vital motivation to all subsequent research on UCB. 
The first unrelated umbilical cord blood transplant (UCBT) was performed in 1993 on patients with malignant and 
non-malignant diseases (Kurtzberg et al., 1996). In 1996, Laporte et al reported successful UCBT in an adult with 
chronic myelogenic leukemia from an unrelated donor (Laporte et al., 1996). This innovative use of stem cells has 
led to a wide increase of UCB banking. As a result, expecting mothers are now more likely to bank their newborn‘s 
UCB in cord blood banks (CIBMTR) (Pasquini & Wang, 2010). 
Here, we provide a review of the most recent research performed on UCBTs.  We first examine the 
essential constituents of UCB including HSCs and mesenchymal stem cells (MSCs). We further review the 
advantages and disadvantages of UCBT HSCs as opposed to bone marrow transplant (BMT) HSCs by examining 
clinical trials. Since there are less HSCs in UCB than in BM, we discuss methods that overcome the limitation of 
HSCs from a single cord through double cord blood transplantation (DCBT) and ex-vivo expansion. Additionally, 
we analyze clinical studies performed on DCBT which use various types of conditioning regimens including 
reduced intensity conditioning (RIC), myeloablative conditioning (MAC), and non-myeloablative conditioning 
(NMAC). Lastly, we discuss the processes of UCB extraction, cryopreservation and banking.  
2. Essential Constituents of Umbilical Cord Blood 
The umbilical cord (UC) is the basic life-line support for all newborns.  It is the essential tube in which all 
nutrients and nourishments are transported from the mother to the embryo.  Following delivery, the umbilical cord is 
usually clamped and discarded.  The human umbilical cord begins to form in the first 5 weeks of pregnancy. The 
allantois, a membrane formed out of the gut, contains umbilical vessels that attach the fetus to the developing 
placenta.  Blood vessels typically develop from the yolk sac, which will then combine with the umbilical vessels. 
The amnion or the membrane surrounding the amniotic fluid envelops the allantois and the yolk sac, forming the 
developing umbilical cord. In the following months leading up to birth, the umbilical cord begins to insert deeper 
into the abdomen of the fetus (Kurt Benirschke & Peter Kaufmann, 2000). The umbilical cord consists of two 
arteries and one vein arranged in a helical structure (Figure 1). The two arteries of the umbilical cord spiral around 
the umbilical vein, making them stiffer and more difficult to rupture. Opposite to the arteries and veins of the human 
heart (except for the pulmonary arteries), umbilical cord arteries and veins carry deoxygenated blood to the placenta 
and oxygenated blood from the placenta to the developing fetus, respectively. The three vessels of the umbilical cord 
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are embedded in a connective tissue gelatinous base known as the Wharton‘s Jelly which insulates the umbilical 
cord. 
 A striking difference between the umbilical arteries and vein is observed in the endothelial cells at 10 
weeks gestation. The endothelial cells of the arteries become richer in glycogen. At 15 weeks gestation, veinous 
endothelium contains the most amount of rough endoplasmic reticulum and thereafter decreases until almost none is 
seen by mid-pregnancy.  Arterial endothelium contained rough endoplasmic reticulum that progressively increased 
over the course of the pregnancy.  
2.1 Hematopoietic Stem Cells  
HSCs are multipotent and have the capability to self-renew and differentiate into all mature blood cells 
including myeloids such as granulocytes, monocytes, leukocytes, erythrocytes, and megakaryocytes, and lymphoids 
such as T-lymphocytes and B-lymphocytes (Figure 2) (Gunsilius, Gastl, & Petzer, 2001; Higuchi et al., 2010). 
HSCs in UCB are similar to those in BM and peripheral blood in their capacity for differentiation. They can self-
renew and they contain erythroid and granulocyte-macrophage progenitor cells when examined in an in vitro colony 
assay (Broxmeyer et al., 1989). 
Current scientific investigation is attempting to determine the best marker for HSCs.  The most recent 
significant constituents of UCB are erythrocytes, endothelial cells, MSCs, HSCs, and Tregs.  Many other 
mononuclear cells are found in UCB, making it difficult to identify HSCs.  A common marker used is cell 
determinant-34 (CD34), a glycoprotein found on the surface of the HSCs and progenitor cells that is important for 
adhesion with neighboring cells (Soiffer, 2008). Simple combinations of markers that efficiently select for HSCs 
have not yet been determined. Protocols experimenting with complex combinations of markers have provided a 
more efficient method of detecting these stem cells. One such protocol begins by reducing the amounts of cells that 
portray any lineage-specific markers and then using the remaining cells to positively select for Sca-1+ Lineage−c-
kit+ cells (Osawa, Hanada, Hamada, & Nakauchi, 1996). However, this protocol only gives 20% multilineage 
reconstitution (Morrison, Hemmati, Wandycz, & Weissman, 1995; Osawa et al., 1996; Spangrude, Brooks, & 
Tumas, 1995; Wagers, Sherwood, Christensen, & Weissman, 2002). More recently, a protocol using the signaling 
lymphocyte activation molecule (SLAM) family of markers were recognized to distinguish between ‗true‘ HSCs and 
primitive progenitor cells. Microarray analysis was performed on three markers from the SLAM family, and the 
most purified HSCs pertained to CD150+CD244-CD48- cells (Kiel et al., 2005).  
2.2 Mesenchymal Stem Cells 
MSCs have multipotential capabilities to self-renew and differentiate into various cellular lineages 
including adipocytes, osteocytes, chondrocytes, cardiomyocytes, hepatocytes, and nerve cells (Chen, Shao, Xiang, 
Dong, & Zhang, 2008; Kang et al., 2006; Kestendjieva et al., 2008; Romanov, Svintsitskaya, & Smirnov, 2003). 
Their proliferative properties and their ability to migrate to sites of inflammation make MSCs highly desirable for 
tissue engineering and cell-based therapy (Chen et al., 2008; Romanov et al., 2003).    
To date, BM is the most common source of MSCs (Kestendjieva et al., 2008). BM MSCs have certain 
disadvantages such as the invasive nature of aspirating BM, the drop in cell number (1 MSC in 104 nucleated BM 
cells at birth to 1 in 2x106 at the age of 80) and reduction of proliferative potentials with donor‘s age (Kestendjieva 
et al., 2008). UCB provides an alternative source of MSCs that possess better proliferative capabilities than BM 
MSCs (Rodeck & Whittle, 2009; Wang et al., 2004).  
Previous research by Panepucci et al. (Panepucci et al., 2004) and Jeong et al. (Jeong et al., 2005) showed 
that MSCs from UCB have similar differentiative properties to MSCs from BM. Similarities include abilities to 
differentiate into adipose tissue, neuronal tissue, bone forming capacity, hepatocyte-like cells, neuroglial-like cells, 
bone and cartilage (Rodeck & Whittle, 2009). Moreover, MSCs from UCB show similar cell morphology and 
immune phenotype to MSCs from BM (Kern, Eichler, Stoeve, Kluter, & Bieback, 2006; Romanov et al., 2003). 
However, previous attempts to isolate MSCs from UCB have been unsuccessful or have resulted in low yields 
(compared to yield rates of 100% from BM) (Bieback, Kern, Kluter, & Eichler, 2004; Kern et al., 2006). Recent 
research has shown that UCB MSCs may be expanded due to their higher proliferation rate and long culture period 
(Kern et al., 2006). 
Similar to HSCs, surface markers used to identify MSCs are not specific to MSCs but also to other cellular 
lineages (Bieback & Kluter, 2009; Li, Gollapudi, Patterson, Huang, & Tuan, 2010; Westwood & Clements, 2007). 
Therefore, a combination of expressed and non-expressed markers are used to identify MSCs. Positive MSC 
markers include CD29, CD44, CD73 (SH-3, SH-4), CD90 (Thy-1), CD105 (SH-2, Endoglin), and CD166 whereas 
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negative markers include CD11, CD14, CD19, CD31, CD34, CD45, and CD79 (Bieback & Kluter, 2009; Li et al., 
2010; Westwood & Clements, 2007).  
2.2.1.MSCs as Immunoregulators 
MSCs are considered to assist in lowering graft-versus-host-disease (GVHD) in UCBT (Ringdén et al., 
2006). This may be attributed to the ability of MSCs in reducing T-cell proliferation and cytokine production 
(Aggarwal & Pittenger, 2005; Glennie, Soeiro, Dyson, Lam, & Dazzi, 2005; Maitra et al., 2004). Exact mechanisms 
of how MSCs  perform their immunosuppression remain unknown.  It has been suggested that factors such as 
transforming growth factor- (TGF-), nitric oxide, and interleukin-10 (IL-10) co-function with MSCs to cause 
immunosuppression (Batten et al., 2006; Groh, Maitra, Szekely, & Koç, 2005; Sato et al., 2007). Further research is 
required to determine the feasibility of using MSCs along with UCB HSCs to lower GVHD and improve 
engraftment rates.   
2.3 Regulatory-T Cells as Immunoregulators 
T-regulatory cells (Tregs) are immune suppressor cells that restrain allogeneic immune responses.  Their 
ability to respond to foreign or self-antigens allows them to maintain the immune system at a homeostasis 
(Sakaguchi, Yamaguchi, Nomura, & Ono, 2008). Tregs are typically characterized as CD4+CD25hi T cells that 
express the fork head box transcription factor (FOXP3) (Fontenot et al., 2005).  FOXP3 is crucial for T cell 
activation and in regulating a variety of immune reactions.  It is also the most reliable marker for Tregs. 
Tregs in UCB may play a crucial role in hematopoietic stem cell transplants (HSCT). Studies on mice 
administered with allogeneic HSCs have determined that the depletion of Tregs triggers an increased T cell response 
to tumors, self-antigens, and pathogens, resulting in increased GVHD in recipients (Anderson et al., 2004; Chen et 
al., 2007; Cohen, Trenado, Vasey, Klatzmann, & Salomon, 2002; Taylor, Lees, & Blazar, 2002). Conversely, the 
presence of Tregs resulted in fewer cases of GVHD (Taylor et al., 2004; Trenado et al., 2003). Patients who receive 
BM transplants are at a higher risk of developing GVHD as compared to patients who receive UCBT (Kim & 
Broxmeyer). Reasons for such results remain unknown but it is speculated that the lower percentages of GVHD in 
UCBT recipients may be due to the Tregs present in UCB (Kim & Broxmeyer). The lack of human clinical trials, 
mainly due to the complexity of isolating human Treg populations, makes it difficult to validate such a speculation.    
3. Hematopoietic Stem Cell Transplantation 
Once a HSC unit has been identified for a patient, he/she must first be administered on a conditioning 
regimen 5-10 days before the HSC transplant (Carrier & Ledingham, 2004).  Conditioning regimens are 
chemotherapy only or chemotherapy combined with total body irradiation (TBI) treated to patients undergoing 
allogeneic HSCTs (Vriesendorp, 2003). The conditioning regimen destroys diseased cells in the patient‘s body, 
opens up space in the bone marrow for new cells, and reduces the risk of rejection by suppressing the immune 
system (Bacigalupo et al., 2009; Casper et al., 2004). The intensity of the conditioning regimens given to patients is 
crucial and may vary according to age or comorbidities (Nakamae et al., 2009). One of the most common 
conditioning regimens for patients with acute leukemia or high-risk lymphoma is cyclophosphamide combined with 
total body irradiation (Cy/TBI).  TBI is radiation performed to the entire body as opposed to the specific infected 
area.  This therapy aids in suppressing the patient‘s immune system to allow for reduced rejection of the transplant.  
Another common type of conditioning regimen includes busulfan and cyclophosphamide (Bu/Cy) for patients with 
chronic myelogenous leukemia (CML).  Along with the conditioning regimen, the patient receives chemotherapy 
treatments.  Many of these preparatory therapies for transplant are associated with side effects and risk factors that 
patients must be informed of beforehand.  
3.1 Conditioning regimens  
There are three common categories of conditioning regimens: (1) myeloablative conditioning (MAC), (2) 
non-myeloablative conditioning (NMAC) and (3) reduce intensity conditioning (RIC). 
MAC regimens are associated with irreversible pancytopenia and myeloablation. Such conditioning 
requires stem cell support (Bacigalupo et al., 2009). MAC is administered to young patients (<50 years of age) 
without comorbidities due to its high toxicity (Mielcarek & Storb, 2003). Even in young patients, MAC is associated 
with high treatment related mortality rates (Kanda et al.; Vriesendorp, 2003). Common MAC regimens include 
either cyclophosphamide 120 mg/kg and TBI (12 to 14.4 Gy) or 16 mg/kg busulfan (Mielcarek & Storb, 2003). Such 
combination of high doses of TBI and/or alkylating agents is so intense that autologous hematologic recovery is 
disabled and thus hematopoiesis in patients can only be restored by transplanted HSCs (Bacigalupo et al., 2009).  
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Bacigalupo et al. defined NMAC regimens as those that cause minimal cytopenia and do not require stem 
cell support (Bacigalupo et al., 2009). NMAC regimens are developed to reduce toxicity in HSCTs. Such reduction 
in cytotoxicity provides better results in HSCTs with older or medically weak patients (Mielcarek & Storb, 2003). 
NMAC is associated with minimally myelosuppressive regimens combined with intensive immunosuppression post-
transplant to ensure engraftment (Nakamae et al., 2009). NMAC regimens include the use of fludarabine and/or 
reduced chemotherapy and radiation (Bacigalupo et al., 2009). Fludarabine is important in NMAC due to its ability 
to reduce high rate of graft rejection (Horwitz & Chao, 2010). Common NMAC regimens include combinations of 
busulfan/fludarabine or TBI 200 cGy/fludarabine (Horwitz & Chao, 2010). In addition, patients are treated with 
cyclosporine and mycophenolate mofetil as post-graft immunosuppression (Horwitz & Chao, 2010; Nakamae et al., 
2009). 
RIC regimens can neither be defined as MAC or NMAC. Compared to MAC, RIC has a minimum TBI or 
alkylating agent dosage reduction of 30% (Bacigalupo et al., 2009). It differs from NMAC in that RIC causes 
prolonged cytopenia and requires stem cell support (Bacigalupo et al., 2009). According to the Center for 
International Blood and Marrow Transplant Research (CIBMTR) and National Marrow Donor Program, RIC 
regimens have to meet one or more of the following criteria (Giralt, 2005): 
1. ≤ 500 cGy total-body irradiation, 
2. ≤ 9 mg/kg total busulfan dose, 
3. ≤ 140 mg/m2 total melphalan dose, 
4. ≤ 10 mg/kg total thiotepa dose and 
5. Includes a purine analog—fludarabine, cladribine, or pentostatin. 
The aim of RIC regimes is to prevent graft rejection and to establish stable donor-derived hematopoiesis 
while maintaining low rates of non-hematologic toxicity (Giralt, 2005; Satwani, Cooper, Rao, Veys, & Amrolia, 
2008).  
The donor HSCs are transplanted after a patient has been placed on a conditioning regimen. The donor 
HSCs are infused into the patient‘s bloodstream through a typical central line.  The HSCs will travel along the 
bloodstream throughout the body for several days, after which they begin to dwell into the spaces of the patient‘s 
bone marrow.  At this point, the HSCs will grow and will begin producing new blood cells after 1-2 weeks.  White 
blood cells will be formed first, then red blood cells, and lastly platelets.  The engraftment, or the process by which 
the patient‘s body accepts the new HSCs, will follow 1-3 weeks after transplantation. 
3.2 BM vs. UCB 
UCBTs are currently one of the most common types of transplants in the United States, as evidenced by the 
increasing number of transplantation centers (Figure 3) (National Marrow Donor Program, 2010b). The outcomes 
of transplants from 6/6 matched BM vs. unrelated UCB have been compared in various studies (Table 1) (Laughlin 
et al., 2004; Rocha et al., 2004; Takahashi et al., 2004). 
A study performed by Laughlin et al. included 150 patients with 1 or 2 HLA mismatched CBUs (Laughlin 
et al., 2004). The study also included 367 patients receiving 6/6 HLA matched bone marrow units and 83 patients 
receiving 5/6 HLA matched BM units. UCBT patients had a median body weight less than BMT patients (68kg vs. 
76kg). UCB patients received ten-fold less total nucleated cells (TNCs) compared to BMT patients (0.22×108 vs. 
2.4×108 per kg of body weight). The recovery times for neutrophils (>500 cells/mm3) and platelets (20 000 
cells/mm3) were both delayed for UCBT recipients compared to BMT recipients (27 days vs. 18 days, 95% CI and 
60 days vs. 29 days, 95% CI). Similarly cumulative incidences for neutrophil recovery at 100 days and platelet 
recovery at one year after matched BM transplants were significantly higher than in UCBT. However, compared to 
1-HLA mismatch BMTs, UCBTs resulted in similar cumulative incidences of neutrophil recovery at 100 days 
(p=0.29) and platelet recovery at one year (p=0.16). The rate of acute II-IV GVHD was similar between matched 
BMT and UCBT (48% vs. 41%, 95% CI). Patients who survived after 90 days were assessed for chronic GVHD 
which was higher in UCBT patients than in matched BMT patients (35% vs. 51%). However, UCBT patients 
developed less acute II-IV GVHD occurrences than mismatched BMT patients (95% CI) while chronic GVHD rates 
were similar. TRM was significantly higher in UCBT patients than in matched BMT patients (63% vs. 46%). 
Treatment failures developed in 69% of matched BMTs and 81% of UCBTs. Leukemia relapse was observed in 26 
out of 150 UCBT patients and 83 out of 367 BMT patients. The DFS rate after 3 years was 23% and 33% for UCBT 
and BMT patients, respectively. After 100 days, the rates of death in UCBT patients were significantly higher than 
in matched BMT patients (70% vs. 50%, p<0.001). The proportion of deaths due to infection was higher in UCBT 
patients than in both matched and mismatched BMT patients. Although TRM, rate of treatment failure, and overall 
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mortality were significantly higher in UCBT patients than in matched BMT patients, the rates were similar with 
BMTs that have 1 HLA mismatch.  
A four-year retrospective study by Rocha et al. compared 98 UCBTs and 584 BMTs in patients diagnosed 
with acute leukemia (Rocha et al., 2004). UCBT patients were diagnosed with more advanced leukemia at the time 
of transplantation (p<0.001). The median age and body weight of UCBT patients were both less than BMT patients 
(24.5 years and 58kg vs. 32 years and 68kg). All BMTs were 6/6 HLA matched while 90% of UCBTs were 1-2 
HLA mismatched. Similar to the study by Laughlin et al. (2004), UCBT recipients received ten-fold less TNCs 
compared to BMT recipients (0.23×108 vs. 2.9×108 per kg of body weight). ANC (>500 cells/mm3) engraftment was 
significantly delayed in UCBT (26 days vs. 19 days).  Primary graft failure occurred in 43 BMT patients and 20 
UCBT patients while secondary graft failure occurred in four BMT patients and one UCBT patient. UCBT patients 
were significantly less likely to experience acute II-IV GVHD when compared to BMT patients (26% vs. 39%, 
p=0.008) while there was no significant difference in chronic GVHD between the two groups (30% vs. 46%, 
p=0.07).  A two-year follow-up demonstrated that TRM and DFS were insignificant between the two groups (44% 
vs. 38%, p=0.13, and 33% vs. 38%, p=0.06). 
A single center study was performed in Japan by Takahashi et al. in 2004 comparing 68 UCBTs and 45 
BMTs (Takahashi et al., 2004). Median age of UCBT patients was higher than BMT patients while median weight 
was higher in BMT patients (36 years and 55.1kg vs. 26 years and 59.6kg).Out of 68 UCBT patients, 75% received 
4-5/6 matched CBUs. Most of BMT patients received matched BMTs while only six patients received 5/6 HLA 
matched BMTs. The patients underwent MAC regimens consisting of cyclophosphamide and TBI. UCB grafts 
contained more than 2.0 x 107 cells per kg and a median of 0.9 x 105 CD34+ progenitor cells per kg. Within 28 days 
after transplantation, 4% of UCBT patients died while 8% experienced primary graft failure. UCBT recipients had a 
delayed ANC (>500 cells/mm3) engraftment than BMT recipients (22 days vs. 18 days). Platelet (>20 000 
cells/mm3) recovery was observed after 40 and 25 days for UCBTs and BMTs, respectively. The overall myeloid 
engraftment rates on day 42 were 92% for UCBT and 100% for BMT. Despite higher HLA mismatches in UCBTs, 
acute II- IV and III-IV GVHD incidences were lower than BMTs. Among the patients surviving 100 days after 
transplantation, 78% of patients receiving UCBTs and 74% of those receiving BMTs were affected by chronic 
GVHD. The hazard ratio for one-year TRM incidence was lower in UCBT patients compared to BMT patients (0.32 
vs. 1.0, 95% CI). However, although there is no apparent risk of relapse in the two groups (p=0.73), relapse was 
slightly lower in UCBT recipients (hazard ratio of 0.76 vs. 1.0, 95% CI). DFS was significantly better among 
patients receiving UCBTs than BMT patients (74% vs. 44%). Deaths of BMT patients were more likely due to 
GVHD while no correlation between death and GVHD was observed in UCBT patients. TRM and DFS rates were 
surprisingly better in UCBT patients than in BMT patients compared to other studies (Laughlin et al., 2004; Rocha 
et al., 2004). A possible explanation for the improved TRM and DFS rates in this study is that it evaluated patients 
only from a single center. Lower incidences of acute II-IV GVHD may be explained due to lower degree of diversity 
for HLA and minor histocompatibility antigens among more homogenous population in Japan. Moreover, it has 
been shown that the Japanese population expresses a higher frequency of the gene that induces interleukin-10 
production which may also contribute to lower acute II-IV GVHD incidences (Lin et al., 2003). 
3.2.1 Advantages vs. Disadvantages 
Based on the UCBT and BMT studies performed one can determine the advantages and disadvantages of 
both transplant types. Compared to HSCs from BM, HSCs from UCB are able to engraft not only with reduced 
GVHD, but also with less severe cases of GVHD (Rocha et al., 2004).  A possible reason may be due to 
immunoregulators such as Tregs or MSCs, as described earlier, that are mixed in with UCB. In addition, UCB allow 
for more diverse transplants due to its ability to engraft despite a higher degree of HLA mismatch. BMTs require at 
least a 5/6 HLA match while UCBTs require at least a 4/6 HLA match (although a 3/6 match has also proved to be 
functional) (J. N. Barker et al., 2002). This allows for a much higher probability for finding a patient-donor match.  
A statistical analysis has shown that patients seeking a CBU will be able to find a 4/6 HLA match 99% of the time 
(Beatty, Boucher, Mori, & Milford, 2000; Stevens, Scaradavou, Carrier, Carpenter, & Rubinstein, 2005).  The 
probability of finding a 5/6 CBU with a sufficient cell dose (>2×107 TNC/kg) is 80% given that at least 170 000 
CBUs are available. Moreover, if a patient is identified for an HSC transplant, the process of finding a CBU match is 
quicker (days-weeks) than identifying a match for a BMT (weeks-months). The average time for identifying a donor 
of a CBU is 13.5 days while it is 45 days to identify a BM donor (Barker et al., 2002).  It is faster to identify a 
matching CBU because it will be available for transplant as soon as the unit is identified. It takes longer to acquire a 
BMT because first, a donor must be identified (average of 19 days), and second, a 30-day period necessary to clear 
the donor (J. N. Barker et al., 2002). Extraction of HSCs from UCB is noninvasive compared to extraction of HSCs 
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from BM. While BMTs require the use of pervasive extraction procedures (aspiration) which will exert some pain to 
the donor, cord blood permits easy access to stem cells with no pain to the mother or the newborn. Furthermore, 
extracting HSCs from BM can lead to donor infection. 
A disadvantage of UCB is that the patient has both a longer time-to-neutrophil recovery and time-to platelet 
recovery.  Clinical trials have shown that UCB displayed a time-to-neutrophil recovery (neutrophils > 500 
cells/mm3) ranging from 22-27 days as opposed to an average of 18 days for unrelated BMTs (Taghizadeh & 
Sherley, ). Moreover, UCB presented a time-to-platelet (platelets > 20 000 cells/mm3) recovery of 60 days compared 
to 29 days for BM transplants (Laughlin et al., 2004).  Similarly, another clinical trial exhibited a time-to-neutrophil 
recovery (neutrophils > 500 cells/mm3) average of 27 days for HLA mismatched UCB and 19 days for HLA 
matched BM recipients (Rocha et al., 2004). 
The TNC dose transplanted per kg of body weight is directly correlated with the outcomes of the 
transplantation (Lim et al., 1999; Tung, Parmar, Robinson, De Lima, & Shpall, 2010). TNC dose is critical in 
neutrophil recovery and higher CD34+ cell counts, which is associated with higher engraftment rate, TRM, and 
improved survival (Barker et al., 2005; Tung et al., 2010). Patients receiving UCBTs of cell doses less than 1.8×107 
TNCs and 1.7×105 CD34+ cells per kilogram of the recipient body weight had inferior engraftment and survival rates 
(J. E. Wagner et al., 2002). On average, TNCs in UCB are approximately 10 fold lower than BM. These low 
amounts of CD34+ cells may provide an explanation for the delayed engraftment of UCBTs (Eapen et al., 2007; 
Laughlin et al., 2004; Rocha et al., 2004; Takahashi et al., 2007). Laboratory techniques as well as purification 
procedures are currently being explored to determine the most efficient methods of collecting or culturing CD34+ 
cells. 
4. Double Cord Blood Transplantation 
Due to the limited cell dose available from one CBU, UCBTs are more ideal for younger, lower weight, 
patients. Even in UCBTs with small children, delays in engraftment and immune reconstitution are observed 
compared to other stem cell sources (Tung et al., 2010). Additionally, patients with a total body weight of more than 
45 kg who receive only one CBU are associated with decreased neutrophil and platelet recovery and higher rates of 
engraftment failure (Tung et al., 2010). In order to overcome low cell dose in UCB HSCs, two methods are often 
employed, DCBT and ex vivo expansion.   
In DCBT, two CBUs, each of which has no more than 2/6 HLA mismatches (low resolution typing of 
HLA-A and –B or high resolution typing of HLA-DRB1), are infused together to transplant into adults and large 
children (Barker et al., 2005; Brunstein et al., 2007; Rocha et al., 2010; Wagner, 2009). The two CBUs chosen for 
transplantation must have at least a 4/6 HLA match between the units themselves and with the patient.  
When a CBU is selected for transplantation, the TNC dose is used to determine if a single unit is sufficient 
for treatment (Figure 4) (Barker et al., 2005; Brunstein et al., 2007; Wagner, 2009). A minimum TNC dose of 2.5-
3×107 per kg of body weight is recommended for each of the two closely matched (5/6 or 6/6 matches) UCB units 
(Tung et al., 2010). A greater mismatch between the two CBUs requires a higher TNC count (Tung et al., 2010).  
Research suggests use of two CBUs if a single HLA-matched unit has TNC dose of < 3.0×107 per kg (Brunstein et 
al., 2007; Wagner, 2009).  However, Barker et al. (Barker et al., 2005) performed DCBTs on patients when the TNC 
dose of a single unit was less than 3.5×107 per kg in order to increase graft cell dose for patients. Barker et al. 
(Barker, Scaradavou, & Stevens, 2010) further suggested that if the CBU is only 4/6 HLA matched, then the cell 
dose should be as high as 5.0×107 per kg.  
4.1 DCBTs using different conditioning regimens  
Various DCBT studies have been performed separately on MAC, NMAC, and RIC (Table 2) (Ballen et al., 
2007; Barker et al., 2005; Barker et al., 2009; Brunstein et al., 2007; Cutler et al., 2010; Kanda et al., ; Majhail, 
Brunstein, & Wagner, 2006; Rodrigues et al., 2009; Verneris et al., 2009; Yoo et al., 2011). The largest MA study 
performed by Verneris et al. included 93 DCBT patients and 84 single UCBT patients all diagnosed with acute 
leukemia or transplantation in first or second complete remission (CR1-2) (Verneris et al., 2009).  Median age and 
weight of DCBT patients were 24 years (range 9-57 years) and 69kg, respectively. At least 90% of DCBT and single 
cord recipients received two 4-5/6 HLA matched units. The majority of AML and ALL patients were in CR1 or 
CR2, and a sub-majority who underwent transplantation in CR1 had high risk clinical features. DCBT recipients 
received a median infused TNC dose of 3.6×107 per kg of body weight while single cord recipients received a 
median dose of 3.3×107 per kg of body weight. ANC engraftment recovery was similar between the two groups.  
Grade II-IV acute GVHD occurred more frequently in DCBT patients than single cord patients (48% vs. 29%, 
p<0.01). A similar trend is observed with chronic GVHD (18% vs. 10%, p=0.06). Relapse was significantly lower 
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in CR1-2 DCBT patients than single cord blood transplant patients (16% vs. 31% p <0.03). Verneris et al have 
determined that two risk factors were associated with relapse, 1) disease state 2) use of two partially matched CBUs. 
DFS was similar among the two groups after 5 years (51% vs. 40%, p=0.35). A DCBT study by Barker et al. 
included recipients of a similar age group. They received similar amounts of TNCs, which resulted in analogous 
ANC engraftment (Barker et al., 2005). Correspondingly, more patients were likely to have acute II-IV GVHD than 
chronic GVHD (65% and 23%).  DFS after 10 months was achieved in 57% of patients. Similar occurrences were 
observed in other clinical studies (Barker et al., 2009; Kanda et al.). 
The largest NMA study using two units of UCB was performed by Brunstein et al. and included 93 patients 
diagnosed with high risk hematologic diseases (Brunstein et al., 2007). Median age and weight of patients were 51 
years and 76 kg, respectively.  The majority of recipients received two 4-5/6 matched units. Patients received 
combined median TNC dose of 3.7×107 and median CD34+ dose of 1.2×107 per kg of body weight. ANC 
engraftment recovery was achieved after 12 days.  There were fewer cases of chronic (23%) than acute II-IV GVHD 
(59%). Acute GVHD did not associate with HLA matching. A three-year follow up assessed a 38% DFS and TRM 
of 26%. Preexisting high-risk clinical features seemed to be the primary predictors of increased TRM as patients 
lacking these features showed low TRM. Overall survival was not influenced by age but was rather attributable to 
severe GVHD and preexisting high-risk clinical features. Chimerism of the two UCB units was observed in 81 
patients.  Chimerism from each CBU decreased over time (43% at day 21, 9% at day 100, and 0% at one year) until 
one unit predominated. The contribution of donor-derived cells to the predominant unit was 7% at day 21 and 0% at 
day 100. Factors including cell doses and HLA matching were not predictive of the dominating unit. A possible 
reason that a relationship was not observed might be attributable to the sequential (~1 hour) infusion of the two 
units. Ballen et al allowed 3.5-4.5 hours between the infusion of the first and second unit, and observed that the first 
unit infused predominated 76% of the time (Ballen et al., 2007).  
In a previous study performed by Ballen et al., 21 patients were treated by same RIC with 
fludarabine/melphalan/rabbit antithymocyte globulin but different GVHD prophylaxis consisted of cyclosporine and 
mycophenolate mofetil. The median age and weight were 49 years and 78 kg respectively. The median infused TNC 
dose was 4.0x107 and that of CD34+ was 1.9x105 per kg. After transplantation, two patients experienced primary 
graft failure. Among the remaining patients, the median time to ANC (>500 cells/mm3) and platelet count (>20 000 
cells/mm3) were 20 days and 41 days respectively. Grade II-IV acute GVHD developed in 40% of the patients. 
Among 16 patients evaluable, 31% suffered chronic GVHD. TRM was 14% at day 100 and 19% at 6 months. The 
two year follow up for OS and DFS were 71% and 55%. Chimerism was evaluated among 17 patients. Both donor 
units were initially identified in 6 patients. However, after 12 weeks post-transplantation, single unit predominance 
was observed in 13 patients, double cord chimerism was observed in 1 patient, and host hematopoiesis along with 
single cord blood was observed in 3 patients. Of all the patients with single unit predominance, the predominant unit 
infused first (p=.049) and generally had higher TNC (p=.071) and CD34+ (p=.120) counts. 
Cutler et al. recently performed a study describing their experiences with 32 patients who underwent 
DCBT. All patients received RIC of fludarabine (180mg/m2), melphalan (100mg/m2) and rabbit antithymocyte 
globulin(6.0mg/kg) and received sirolimus, which is a potent immunosuppressant that prevents T-cell mediated 
alloimmunmity, and tacrolimus to prevent acute GVHD. The median age and weight of the patients were 53 years 
and 75.9 kg respectively.  Majority of patients (91%) received two 4-6/6 units. UCB units engrafted had a minimum 
required combined cell dose of 3.7x107 TNC/kg before cryopreservation and each individual unit had 1.5x107 
TNC/kg pre-cryopreservation. The median pre-cryopreserved combined doses of TNC and CD34+ progenitors were 
5.16x107 and 1.9x105 per kg respectively. The two CBUs were administered sequentially 1 and 6hr apart, with the 
unit with higher pre-cryopreservation TNC dose being administered first. Patients achieved ANC (>500 cells/mm3) 
ranging from 13-70 days (median = 21 days) and platelet engraftment at 42 days. Grade II-IV acute GVHD 
developed in three of 32 patients and chronic GVHD developed in four of 32 patients. Non-relapse mortality at 100 
days and 2 years were 12.5% and 34.4% respectively. Chimerism was evaluated among 29 patients who survived, to 
determine the relative contribution to hematopoiesis. At day 100, 62% of the surviving patients showed evidence of 
single CBU dominance while both units contributed to hematopoiesis in the remaining patients. The first infused 
unit was observed to be responsible for the majority of hematopoiesis in 61% of the patients who showed single 
CBU dominance. Among the patients with single cord predominance at day 100, 67% had only single unit 
contributing to hematopoiesis while the remaining patients had evidence of single unit early graft rejection or loss. 
The median time to relapse after transplantation was 12.6 months while DFS and OS at two years were 31.2% and 
53.1% respectively. Comparing to the study performed by Ballen et al, there was no significant difference between 
engraftment rates. However, the incidences of acute GVHD were significantly lower(p=.035). It is speculated that 
the use of sirolimus and tacrolimus GVHD prophylaxis reduced the GVHD occurrence since both studies used the 
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same RIC and UCB selection algorithm. Similar results were achieved in studies performed by Ballen (2007) and 
Rodrigues (2009) in which recipients DFS rates of  55% and 57%, respectively.      
In most patients, only one of the two units gives rise to donor hematopoiesis (Ballen et al., 2007; Brunstein 
et al., 2007; Cutler et al., 2010). However, this strategy has been shown to improve engraftment (Scaradavou et al., 
2010).  Moreover, a reduced risk of relapse but higher incidence of acute GVHD may be associated with DCBT 
compared to single UCBT (Rocha et al., 2010; Scaradavou et al., 2010).  
4.1.1 Double vs.  Single Cord Blood Transplantation Using Myeloablative Conditioning 
There is great difficulty in drawing conclusions from data results when there isn‘t much data to consider. 
DCBT TNCs were normally greater than 3.5*107 which is approximately two fold greater than single UCBTs.  ANC 
engraftment rates were similar between double and single UCBTs that use MA conditioning regimens. The ANC 
engraftment days for DCBTs were 23, 24, 25, and 25, which are comparable to results using single UCBTs.  
Prevalence of acute II-IV GVHD were diverse among studies in both single and DCBTs, however, the rate of acute 
II-IV GVHD seemed higher in DCBTs.  Chronic GVHD were also diverse between studies of single and DCBTs, 
but overall seemed to be lower in DCBTs. The percentage of DFS following one or two years in DCBTs was 57, 52, 
56, and 51, which appeared to be lower than single UCBTs.   
5. Ex Vivo Expansion 
The other method of overcoming low cell dose of UCB is expansion of UCB HSCs. Primitive 
hematopoietic progenitor cells such as CD 133+ and CD 34+ from UCB are cultured with cytokines, growth factors 
and other growth promoting compounds in liquid culture(Tung et al., 2010). The growth factors that are cultured 
with hematopoietic progenitor cells usually include stem cell factor (SCF), interleukin (IL)-3, IL-6, granulocyte 
colony-stimulating factor (G-CSF), thrombopoietin (TPO) and Flt-3 Ligand (FL) (Tung et al., 2010). Several other 
techniques have been attempted to further improve the expansion such as the use of histone deacetylases to promote 
HSC self-renewal, glycogen synthase kinase-3 inhibitors to maintain pluripotency of stem cells and 
tetraethylenepentamine to stimulate ex vivo expansion of hematopoietic progenitors (Peled, Landau, Prus, Treves, & 
Fibach, 2002; Sato, Ozaki, Oh, Meguro, Hatanaka & Nagai, 2007; Young et al., 2004). 
Another technique to expand UCB is to provide a microenvironment for HSCs that will regulate 
differentiation and proliferation of HSCs and provide cues that direct hematopoiesis (Tung et al., 2010). One 
potential attempt to accomplish this is by co-culturing HSCs with MSCs. MSCs derived from the Wharton‘s jelly of 
an UC provide stromal support for cord blood HSCs. (Bakhshi et al., 2008) In the long-term culture-initiating cell 
assay, UC MSCs were proven to effectively support the growth of CD34+ cells from UCB. Other research suggests 
co-transplanting MSCs with HSCs in UCBTs (Noort et al., 2002). Co-transplantation may promote engraftment of 
UCB CD34+ cells. McNiece et al. (McNiece, Harrington, Turney, Kellner, & Shpall, 2004) isolated and cultured 
mononuclear cells from UCB on MSC layers ex vivo and observed a 10-20 fold increase in TNC,  a 7-18 fold 
increase in committed progenitor cells, a 2-5 fold increase in primitive progenitor cells and a 16-37 fold increase in 
CD34+ cells after 14 days. Based on previous research, co-culturing HSCs with MSCs may prove to be a potentially 
effective therapeutic application in HSC transplantation. 
6. Blood Extraction and Processing 
UCB is currently collected for one of two reasons– (i) donation for public use or (ii) storage for self or 
family members who are suffering from a disease that can be cured by HSC transplantation (Ballen, Barker, Stewart, 
Greene, & Lane, 2008). Expecting mothers must meet certain criteria to be eligible to donate UCB of the newborns. 
The general eligibility guidelines for expectant mothers, according to the National Marrow Donor Program 
(National Marrow Donor Program, 2010a), are listed below: 
(i) Be at least 18 years of age  
(ii) Have no history of hepatitis B or C, HIV, medication-dependent diabetes and cancer  
(iii) Have no history of organ transplantation  
(iv) Have no history of sexually transmitted diseases within the last 12 months 
(v) Have not had tattoos, non-sterile piercings or acupuncture done in the previous 12 months 
(vi) Have no malaria history within last three years 
 
UCB is collected after delivery either before placental separation from the uterus wall or after placenta 
delivery (Ballen et al., 2008). Lifeforce Cryobanks, ViaCord and New England Cord Blood Bank have similar 
procedures of collecting UCB (Lifeforce Cryobanks, 2011; New England Cord Blood Bank, 2011; ViaCord, 2011). 
The cord of the baby is clamped and cut postnatally. After the UC is rinsed with antiseptic solution, the umbilical 
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vein is punctured with a needle connected to a standard blood collection bag that contains anticoagulant. Blood 
flows into the bag by gravity, and after flow stops, the bag is detached and stored away for further processing. This 
simple procedure used by UCB banks corresponds with the UCB collection technique by Adami et al. (Adami et al., 
2005). In this method, the UC was double clamped within 30sec after newborn delivery, and blood was collected 
while placenta was in utero. The anticoagulant used in the collection bag was citrate-phosphate-dextrose. A similar 
procedure has been done by Elchalal et al., except that the cord was ligated before clamping to avoid tissue crushing. 
The UC was then cut between the clamp and ligation. Moreover, massaging or ―milking‖ of the cord was performed 
at the end of blood flow (Elchalal et al., 2000).   
It is important to be cautious when collecting UCB to obtain high-quality CBUs for transplantation. The 
major issues involved with UCB collection include the volume of UCB collected, microbial infection, delay in blood 
collection, and blood coagulation (Ballen et al., 2008). 
6.1 Cryopreservation 
The storage process for HSCs is termed cryopreservation and is outlined in Figure 5.  UCB is first treated 
with chemicals such as starch or ammonium chloride to reduce plasma and red blood cell (RBC) counts. RBCs 
typically lyse easily when they are frozen or thawed. Research suggests that these cell lysates may have detrimental 
effects when the HSCs are used for transplants (Regidor et al., 1999). Chemical treatment additionally helps reduce 
blood volume, allowing for easier storage and reduction of cellular debris upon thawing. Once RBCs are depleted, a 
freezing medium containing dimethyl sulfoxide (DMSO) is added.  DMSO is a cryoprotectant that helps preserve 
the cells from the sub-zero temperatures used during the cryopreservation process.  The HSCs will freeze at a 
controlled rate of 1C /1 min until -80C. This process is usually carried out overnight.  Several studies have 
indicated that freezing cells at a controlled rate increases cell viability (Perez-Oteyza et al., 1998, Balint et al., 
2006). The HSCs will then be transferred into a liquid nitrogen tank at a temperature of -196C.  The nitrogen tank 
typically consists of numerous compartments that help in the labeling and identification process.   
6.2 Banking 
There are two types of UCB banks, public and private (Table 3).  Public banking is the more widely used 
of the two and stores donated stem cells to the public registry. Access to stem cells is provided on a first-come first-
serve basis. The donation is done with the consent of the mother and at no cost to the family. When a patient needs 
an UCBT, he/she will have up to a 90% chance of finding a compatible transplant in a public bank (Novello-Garza 
et al., 2008). The costs of the transplant, which are generally covered by insurance, range from $15 000-$25 000.   
Private blood banking stores cord blood exclusively for the family of the newborn.  Mothers who have had 
a history of a particular disease in their family that may require a stem cell transplant in the future typically choose 
this type of banking.  The cord blood transplant is guaranteed to be 100% compatible with the child of the mother.  
However, this percentage decreases drastically to 25% compatibility with any relative (J. Wagner et al., 1996). 
Banking privately costs about $1 500 in down payment and $150-$200 annually.  When a transplant is needed, the 
CBU is released at no cost to the patient.  
7. Conclusion 
DCBT and ex vivo expansion of HSCs have expanded transplantation into all patients, despite of size or 
ethnicity. The results of these expansion techniques require a better understanding of the biological processes that 
occur. The spread and rise of HSC transplantation centers promises further research in the field. Such research may 
reveal better methods for improving overall GVHD and survival rates in patients who receive HSC transplantations. 
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Figure 1. The anatomy of the umbilical cord. (Adapted from University of Alabama at Birmingham Medicine, 
2008 and University of Kansas Medical Center, 2011) 
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Figure 2. Differentiation pattern of HSCs. 
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Figure 3: Locations of HSC transplantation centers in the United States (National Marrow Donor Program, 
2010b).
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Figure 4. The common algorithm used for UCB selection. (Adapted from Wagner, 2009)
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Table 1. Clinical studies comparing unrelated myeloablative single UCBT  vs. 6/6 HLA matched BMT in adults 
     Engraftment  GVHD (%)  
Study N-UCB 
N-BM 
Median 
age 
(years) 
Diagnosis Median 
infused 
TNC x 
10
8
/kg 
ANC 
(Day) 
Platelets 
(Day) 
Primary 
failure 
(%) 
 Acute II-
IV 
Chronic DFS (%) 
(follow 
up in 
months) 
Rocha¶ 
(2004) 
98 24.5 AML, ALL 0.23 26 N/S 20  26 30 33 (24) 
584 32 2.9 19 N/S 7  39 46 38 (24) 
Laughlin¥ 
(2004) 
150 N/S AML, ALL, CML, 
MDS 
0.22 27 60 30  41 51 23 (36) 
367 N/S 2.4 18 29 N/S  48 35 33 (36) 
Takahashiŧ 
(2004) 
68 36 AML, ALL, CML, 
MDS, NHL 
 0.25 22 40 8  50 78 74 (24) 
39 26 N/S 18 25 0  75 74 44 (24) 
Abbreviations: ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, CML = chronic myelogenous leukemia, NHL = non-Hodgkin‘s lymphoma, 
MDS = myelodysplastic syndrome, TNC = total nucleated cell, ANC = absolute neutrophil count, GVHD = graft versus host disease, DFS = disease free 
survival, N/S = not stated 
¶ For UCBTs, 6 patients received 6/6 HLA-matched units, 85 patients received 4-5/6 HLA-matched units, and 4 patients received 3/6 HLA-matched units.  
¥ All UCBT patients received 4-5/6 HLA-matched units.  
ŧ BMT outcomes also include 6 patients who received 5/6 HLA-matched units. For UCBTs, 51 patients received 4-5/6 and 17 received 2-3/6 HLA-matched units. 
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Table 2. Clinical results of DCBTs using MA/NMA/ or RIC conditioning regimens in adults 
 Engraftment  GVHD (%)  
Study N-
DCBT 
Median 
age(years) 
Diagnosis Conditioning 
regimen 
Median 
infused 
TNC x 
10
7
/kg 
ANC 
(Day) 
Platelets 
(Day) 
Primary 
failure 
(%) 
 Acute II-
IV 
Chronic DFS (%) 
(follow 
up in 
months) 
Barker 
(2005) 
23 24 ALL, AML, CML MA 3.5 23 N/S 0  65 23 57 (10) 
Cutler 
(2010) 
32 53 ALL , AML, CML, 
NHL, HD, MDS, 
CLL, MD 
RIC 5.16* 21 42 0  9 13 31.2 (24) 
Ballen 
(2007) 
21 49 ALL, AML, CLL, 
MDS, NHL, HD, 
AA 
RIC 4.0 20 41 10  40 26 55 (24) 
Kanda& 
(2010) 
27 33 ALL, AML, CML, 
MDS, NHL, HD 
MA 3.8 24 N/S 12  37 32 52 (24) 
Brunstein~ 
(2007) 
93 51 High risk 
hematologic disease 
NMA 3.7 12 N/S 6  59 23 38 (36) 
Majhail 
(2006) 
9 28 HL RIC 3.8 10 N/S 0  67 11 25 (17) 
Barker 
(2009) 
35 42 Acute leukemia, 
NHL, HD, MDS 
MA 4.46 25 50 6  44 26 56 (12) 
19 NMA 10 38 5  
Rodrigues 
(2009) 
26 41 NHL, HL, CLL RIC 3.02 17 N/S N/S  32 19 57 (18) 
Yoo£ 
(2010) 
64 10.3 ALL/ABL, AML, 
MDS/JMML, SAA, 
CML 
RIC 4.37 19 46 N/S  41 39 36.9 (60) 
Verneris 
(2009) 
93 24 ALL, AML, High-
risk CR1 
MA 3.6 25 N/S N/S  48 18 51 (60) 
Abbreviations (also see Table 1): HD = Hodgkin‘s disease, CLL = chronic lymphocytic leukemia, MD = myeloproliferative disorder, AA = aplastic anemia, HL 
= Hodgkin‘s lymphoma, ABL = acute biphenotypic leukemia, JMML = juvenile myelomonocytic leukemia, SAA = severe aplastic anemia, MA = myeloablative, 
NMA = non-myeloablative, RIC = reduced intensity conditioning, N/A = not available 
*Pre-cryopreservation 
&Article in Press. 
£ Pediatric study 
~ Outcomes include single and DCBTs. 
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Table 3: Comparison between public vs. private UCB banking. 
 
Categories  Public Bank  Private Bank  
Purpose of storage  Donate stem cells to public  Keep stem cells for own children  
Compatibility  Percentage of finding a match 
for a transplant is up to 90%  
Assures 100% match for 
transplantation  
Probability that you will need 
a stem cell transplant  
N/A  Probability to use your own 
UCB is 0.04% - 0.0005%  
Costs to store  Generally covered by insurance  Must pay $1000-2000 to begin 
banking and $100 - $200 
annually  
Costs to retrieve stem cells 
from the bank  
Generally covered by insurance  Does not cost money for 
retrieval  
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Figure 5. The common cryopreservation process of UCB.   
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Appendix I 
Survey Questions 
Stem Cells from Umbilical Cord Blood 
The umbilical cord is typically thrown away after the delivery of the baby. Scientists have 
determined that blood within the umbilical cord is rich in blood-forming stem cells. These stem 
cells are currently banked and used as therapeutic treatments for blood disorders such as 
leukemia and heart disease.  
 
* Required 
 
1. Gender *  
Male 
Female 
2. Are you a student or faculty? *  
Student 
Faculty 
3. Are you aware of umbilical cord blood banking? *  
Yes 
No 
4. Please copy and paste the link below into your browser for an informative and brief video 
on umbilical cord blood banking. Did you find the video useful? * 
http://www.youtube.com/watch?v=DNbE7SVxLf8&fmt=18   
Yes 
No 
5. Would you consider banking umbilical cord blood? *  
Yes 
No 
6. Would you consider public or private banking? *  
Yes 
No 
7. Should federal or state funds be provided for education on umbilical cord blood banking? 
*  
Yes 
No 
8. Should hospitals actively encourage women to donate umbilical cord blood? *  
Yes 
No 
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Survey Responses 
 
Figure 1. Various responses of male WPI students regarding survey questions. 
 
Figure 2. Various responses of female WPI students regarding survey questions. 
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Figure 3. Various responses of male and female WPI students regarding banking options. 
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Appendix II 
 
Email Correspondence with Journal Editor (Global Journal of Health Science) 
 
Sent: Thu 9/9/2010 1:19 PM 
Subject: Article Submission Inquiry (Global Journal of Health Science) 
 
Dear Dr. Song, 
 
My partner and I are junior undergraduate students from Worcester Polytechnic 
Institute, majoring in Biomedical engineering/Mechanical Engineering  and 
Biology/Biochemistry, respectively. 
 
We are currently pursuing a one year long evidence based research project related to 
stem cells extracted from the umbilical cord and umbilical cord blood postnatally.  
Additionally, we plan to examine the ethical and social issues concerning umbilical cord 
blood banking. We are preparing a journal article based on our findings. Please let us 
know if this paper may be suitable for publication in your journal. 
 
Thank you. We are looking forward to hearing from you soon. 
 
Mortada Najem 
Biology/ Biochemistry 2012 
Worcester Polytechinc Institute 
100 Institute Road 
Worcester MA, 01609 
===================================================== 
Kyaw Thu Minn 
Biomedical Engineering/ Mechanical Engineering 2012  
Worcester Polytechnic Institute 
100 Institute Road 
Worcester,  MA 01609 
________________________________________ 
Sent: Thurs 9/9/2010 04:37 PM 
Subject: RE: Article Submission Inquiry (Global Journal of Health Science) 
 
Hi, Kyaw and Mortada 
 
Thank you for your inquiry. Stem cell biology and regenerative medicine are hot research 
fields. Of course, your research is suitable for publication in Global Journal of Health 
Science. 
I am very glad to hear that you guys, as a undergraduate, are interested in stem cell 
research and get some interesting results. I encourage you to submit to our journal and I 
will review your manuscript for you and try to help you publish it after peer-reviewing. 
 
Guisheng Song 
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Email Correspondence with Dr. Mary Herlihy (UMASS Medical Center) 
 
Sent: Fri 9/24/2010 4:11 PM 
Subject: Cord Blood Donation Program 
 
 
 
  
Dear Dr. Herlihy,  
  
My partner and I are junior undergraduate students from Worcester Polytechnic 
Institute, majoring in Biomedical engineering/Mechanical Engineering  and 
Biology/Biochemistry, respectively. We noticed that you have a clinical interest in 
umbilical cord blood donation. We are pleased to learn that you founded the cord blood 
donation program at UMASS Memorial.  
We are also very interested in the umbilical cord blood donation due to its vast benefits. 
We are currently pursuing a one year long evidence based research project related to 
stem cells extracted from the umbilical cord blood postnatally. In addition to the 
information we will obtain from our articles research, we would like to understand more 
on the processes of cord blood collection and donation performed in a hospital setting. 
We believe you can provide us with valuable information for our research. 
This  information will help strengthen our knowledge on the processes of cord blood 
donation, collection and storage. In our research paper, this will help us better portray 
the importance of cord blood donation program to the public.  
Thank you. We are looking forward to hearing from you soon.  
Mr. Kyaw Thu Minn 
Biomedical Engineering/ Mechanical Engineering 2012 
Worcester Polytechnic Institute 
100 Institute Road 
Worcester,  MA 01609 
===================================================== 
Mr. Mortada Najem 
Biology/ Biochemistry 2012 
Worcester Polytechnic Institute 
100 Institute Road 
Worcester MA, 01609 
 
________________________________ 
Sent: Mon 10/27/2010 8:03 AM 
Subject: RE: Cord Blood Donation Program 
 
 
 
  
Certainly - would love to talk. I have included my scertary on this email, she can help 
arrange. 
Often Fridays and Tuesdays are good. 
Look forward to it, Mary 
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Email Correspondence with Dr. Rouzbeh Taghizadeh (Auxocell Laboratories)  
 
Sent:  Fri 10/15/2010 11:42 AM 
Subject: Umbilical Cord Project 
 
Dear Rouzbeh, 
  
 My partner and I have finally made our schedules.  We will be free between 11:00 - 5:00 
Tuesday (October 19)  through Friday (October 22) of next week.  Please let us know 
which day and which time works best for you. 
  
 We are looking forward to seeing you! 
  
 Thank you 
 Mortada Najem 
 
 ________________________________ 
Sent: Tue 10/19/2010 09:18 AM 
Subject: Re: Umbilical Cord Project 
  
 Hello Mortada, 
  
 Let's aim for Friday afternoon from 3-5 PM ... Please let me know if that works for you 
both ... 
  
 Best, 
 Rouzbeh 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
